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Pediatric solid tumors are a diverse group of extracranial solid tumors representing 
approximately 40% of childhood cancers. Pediatric solid tumors are believed to arise as 
a result of disruptions in the developmental process of precursor cells which lead them to 
accumulate cancerous phenotypes. In contrast to many adult tumors, pediatric tumors 
typically feature a low number of genetic mutations in protein-coding genes which could 
explain the emergence of these phenotypes. It is likely that oncogenesis occurs after 
a failure at many different levels of regulation. Non-coding RNAs (ncRNAs) comprise a 
group of functional RNA molecules that lack protein coding potential but are essential in 
the regulation and maintenance of many epigenetic and post-translational mechanisms. 
Indeed, research has accumulated a large body of evidence implicating many ncRNAs 
in the regulation of well-established oncogenic networks. In this review we cover a range 
of extracranial solid tumors which represent some of the rarer and enigmatic childhood 
cancers known. We focus on two major classes of ncRNAs, microRNAs and long non-
coding RNAs, which are likely to play a key role in the development of these cancers 
and emphasize their functional contributions and molecular interactions during tumor 
formation.
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Pediatric cancers are often categorized as hematologic, intracranial, or extracranial (Chen et al., 
2015). Hematologic cancers include those derived from the blood or blood forming tissues, 
including bone marrow and the lymph nodes. Intracranial cancers are tumors that develop inside 
the brain, whereas extracranial solid tumors, often referred to as pediatric solid tumors, arise 
outside the brain. Collectively, pediatric solid tumors represent approximately 40% of all pediatric 
cancers and commonly form in the developing sympathetic nervous system (neuroblastoma), 
retina (retinoblastoma), kidneys (Wilms tumor), liver (hepatoblastoma), bones (osteosarcoma, 
Ewing sarcoma), or muscles (rhabdomyosarcoma) (Kline and Sevier, 2003; Allen-Rhoades 
et al., 2018). Solid tumors can originate from cells of any of the three germ layers, the ectoderm, 
mesoderm, or endoderm, and likely arise due to disruptions in the developmental processes of 
these precursor cells, leading them to develop cancerous phenotypes (Chen et al., 2015). This 
contrasts with most adult cancers, which tend to be of epithelial origin and are believed to develop 
over time due to exposure to toxins and environmental stress. As a result, adult cancers often 
display a high occurrence of genetic mutations, whereas pediatric solid tumors tend to feature a 
relatively low number of genetic mutations. This has led to investigations into alternative forms 
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Non-coding RNAs (ncRNAs) form a group of functional 
RNAs lacking protein-coding potential, which play a 
crucial role in the regulation of gene expression at every 
level, from epigenetic regulation via methylation and 
chromatin packaging to post-transcriptional regulation 
(Cech and  Steitz,  2014; Zhao et al., 2016). The most widely 
studied ncRNAs are the microRNAs (miRNAs), small 20- 
to 25-nucleotide-long RNAs that play an important role 
in regulating translation and messenger RNA stability via 
complementary base pairing (Huang et al., 2011). Other 
classes of small ncRNAs include small interfering RNAs 
(siRNAs), Piwi-interacting RNAs (piRNAs), small transfer 
RNAs (tRFs), small nucleolar RNAs (snoRNAs), small nuclear 
RNAs (snRNAs), and small cytoplasmic RNAs (scRNAs). 
Additionally, long non-coding RNAs (lncRNAs) are a loosely 
defined group of RNAs normally larger than 200 nucleotides 
long that lack protein-coding potential and do not fall into 
any of the other categories but nonetheless play key roles 
in the regulation of gene expression (Mercer et al., 2009). 
Increasing data suggest that ncRNAs play a role in regulating 
all biological processes, and it is no surprise that studies have 
observed widespread dysregulation of ncRNAs in nearly all 
forms of cancer (Prensner and Chinnaiyan, 2011; Leichter 
et al., 2017). Interestingly, dysregulated RNA patterns are 
often specific to the type of cancer or even subtype and can 
provide insight into the mechanisms underlying phenotypic 
differences between tumors or cells within a tumor, such as 
their aggressiveness or resistance to certain types of treatments 
(Blenkiron et al., 2007; Li et al., 2014). Additionally, genome-
wide association studies have suggested that over 80% of single 
nucleotide polymorphisms found associated with cancer are 
outside of coding regions (Carninci et al., 2005; Cheetham 
et al., 2013). In this review, we will discuss how two major 
classes of ncRNAs, miRNAs and lncRNAs, may contribute to 
pediatric solid tumors by participating in the regulation of 
established oncogenic networks known to drive these cancers.
MICRORNAS AND GENE REGULATION
Not long after the first human miRNA, let-7, was discovered 
in 2002 by the Ruvkun lab, miRNAs began to emerge as key 
participants in tumorigenesis (Pasquinelli et al., 2000). In 2002, 
two miRNAs were identified as potential tumor suppressors due to 
their frequent downregulation or deletion in chronic lymphocytic 
leukemia (Calin et al., 2002). Calin et al. (2004) later showed that 
many miRNA genes are located close to fragile sites or common 
breakpoints that frequently occur in cancers, suggesting that 
their loss of function was a key event in oncogenesis. Since then, 
oncomiRs—cancer-associated miRNAs—have become a major 
research focus (Esquela-Kerscher and Slack, 2006). A better 
understanding of the mechanisms behind miRNA regulation 
in cancer is invaluable to researchers and clinicians alike, not 
only to aid in the identification of new drug targets but also for 
the development of promising RNA-based therapies and their 
potential use as early detection biomarkers.
miRNAs: Biogenesis and Functions
The life cycle of a miRNA typically begins with its transcription 
into a primary miRNA (pri-miRNA) by RNA polymerase II 
(Ha and Kim, 2014). pri-miRNAs share several similarities 
with messenger RNAs (mRNAs) in that they are 5’ capped, are 
3’ polyadenylated, and can be several hundreds or thousands 
of nucleotides long. In many cases, the pri-miRNA encodes for 
one miRNA species; however, in humans, a substantial number 
are polycistronic and encode several different miRNAs together. 
pri-miRNAs must be processed in the nucleus by the RNAse  III 
enzyme Drosha, which releases shorter ~65-nucleotide-long 
precursor RNAs (pre-miRNAs) with a secondary hairpin structure. 
This hairpin is recognized by the Exportin-5/Ran-GTP transporter, 
which transports the pre-miRNA from the nucleus to the 
cytoplasm. In the cytoplasm, the pre-miRNA is further processed 
by Dicer, another RNAse III enzyme, which cleaves the loop and 
releases a double-stranded miRNA duplex containing the 5 prime 
(5p) and 3 prime (3p) sequences. The duplex is then recognized by 
one of the four human Argonaute proteins, which loads one of the 
strands and discards the other.
miRNAs carry out their functions by binding to Argonaute 
and associating with various other proteins to form the RNA 
induced silencing complex (RISC). As part of this complex, 
miRNAs serve as guides by binding via complementary 
base pairing to target sites that are normally found in the 
3´-untranslated region (3´UTR) of mRNAs. RISCs can regulate 
gene expression by direct cleavage of transcripts, transcript 
destabilization, or blocking translation. In a broader sense, 
miRNAs play a role in globally “fine-tuning” gene expression 
and are particularly important in inducing and maintaining 
differentiated cell states. In cancer, this finely tuned expression 
is often impaired, enabling gene networks that are normally 
switched on or off to reverse and begin influencing cellular 
behavior in a deleterious manner.
miRNAs: Drivers or Passengers in Cancer?
Microarrays and next-generation sequencing technologies 
enabled global measurements of miRNA expression changes 
and have revealed miRNA dysregulation to be a hallmark in 
nearly all cancers. miRNA expression profiles often correlate 
with cancer subtypes and have been effective at classifying 
cancer samples for risk stratification (De Preter et al., 2011). 
However, understanding the contribution of specific miRNAs 
can prove difficult. miRNAs are predicted to regulate hundreds 
to thousands of genes; however, their influence may be minor, 
and often, they must act in concert with other miRNAs. 
Current miRNA target prediction algorithms are imperfect and 
do not capture the true range of regulatory targets; therefore, 
biological validation is still needed (Riffo-Campos et al., 2016). 
Additionally, opposing behavior is seen with many miRNAs, 
where the same miRNA may be considered an oncogene in 
one cancer and a tumor suppressor in another. Because of 
their integration within complex gene networks, it is often not 
obvious whether a dysregulated miRNA actively participates in 
the maintenance of a cancerous state or whether it is simply a 
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bystander. Therefore, it is important to examine how miRNAs 
participate in oncogenic networks on a functional level in order 
to properly understand their role. 
Transcription factors that play an important role in regulating 
cell proliferation, migration, and apoptosis are commonly 
perturbed in pediatric solid tumors. One of the best examples of 
this is in neuroblastoma, where MYCN amplification is present in 
approximately 25% of neuroblastoma patients and disproportionally 
represents high-risk cases (Huang and Weiss, 2013). MYCN 
upregulation is also observed at a higher frequency in several other 
pediatric solid tumors including Wilms tumor, rhabdomyosarcoma 
(Williamson et al., 2005), and retinoblastoma, although generally 
not to the extent seen in neuroblastoma. Germline inactivation 
of the Wilms Tumor 1 (WT1) transcription factor has been 
linked to a genetic predisposition towards Wilms tumor. Several 
transcription factors, including Twist, Snails, and Zebs, involved 
in the epithelial-to-mesenchymal transition have also been 
implicated in the development of osteosarcoma (Yang et al., 2013). 
miRNAs are often closely tied to transcription factors, either as 
regulators or as transcriptional targets (Figure 1) (Sin-Chan et al., 
2019). One of the earliest studies linking miRNAs to an oncogenic 
transcription factor was by O’Donnell et al. in 2005 (O’Donnell 
et al., 2005). In this study, they demonstrated that c-Myc could 
induce expression of the miR-17~92 cluster and that several of 
these miRNAs could in turn regulate E2F1 transcription to control 
cell proliferation.
Disruptions in miRNA Processing
Recent studies have shown that impairments of the miRNA 
processing machinery are common in Wilms tumor and likely 
contribute to this disease. For example, a study by Torrezan 
et  al. (2014) found mutations in miRNA processing genes in 
33% of tumors, most commonly occurring in the Drosha gene, 
with other mutations in DICER1, XPO5, DGCR8 and TARBP2. 
These results are supported by several other studies by Wu 
et  al. (2013),  Rakheja et al. (2014), Walz et al. (2015), Wegert 
et al. (2015), and Gadd et al. (2017). In Rakheja et al.’s study, 
they further examined the potential consequences of several 
of these mutations and found that Drosha mutations often led 
to a loss of RNAse IIIB activity, which prevented processing of 
FIGURE 1 | Regulatory circuitry involving non-coding RNAs in various pediatric solid tumors. Shows elements of a key regulatory circuit involving MYC and E2F 
family transcription factors and many ncRNAs, often dysregulated in pediatric solid tumors. In many cases, recurring dysregulation of specific elements, including 
miRNAs and lncRNAs, is observed and may represent vulnerabilities in the normal development of specific cell lineages. (A) Loss of chromosomal regions where 
let-7 and miR-34 miRNAs are localized is frequently observed in neuroblastoma and may represent a key event in the development of many of these cancers. 
(B) let-7 dysregulation may facilitate overexpression of the oncogenic fusion transcript EWS-FLI-1 in Ewing sarcoma. (C) The RB1 tumor suppressor regulates E2F, 
and loss of function via mutations can lead to the development of retinoblastoma. In osteosarcoma, miR-9 may be able to act as an oncogenic driver as it is often 
overexpressed and can downregulate RB1. (D) In neuroblastoma, miR-9 can display tumor-suppressive properties by cooperating with miR-125a and miR-125b to 
regulate a specific isoform of trkC and suppress cell proliferation (E) The lncRNA TUG1 is suggested to act as a ceRNA against miR-9, which has been shown to 
display tumor-suppressive properties in some osteosarcoma cell lines.
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pri-miRNAs, leading to a global reduction in mature miRNAs. 
DICER1 mutations also frequently affected the RNAse IIIB 
domain; however, this mutation only affected processing of 5p 
miRNAs from precursors, as DICER1 contains a second RNAse 
domain for 3p processing. As a result, this mutation led to a shift 
towards 3p miRNA maturation. These mutations have interesting 
consequences for global miRNA expression and most likely favor 
expression of oncogenic miRNAs or reduce expression of miRNAs 
with tumor-suppressive effects. In line with this, the let-7 family 
is predominantly 5p-derived, and lower expression of several of 
its 5p members was found in both Drosha and DICER1 mutants 
in two of these studies (Rakheja et al., 2014; Walz et al., 2015). 
Additionally, the miR-200 family was found downregulated in 
Wilms tumors with mutated miRNA processing genes, which is 
known to regulate the mesenchymal-to-epithelial transition and 
has been associated with highly aggressive forms of cancer (Ceppi 
and Peter, 2014; Walz et al., 2015). The functional role of several 
oncomiRs has been investigated in detail within the context of 
pediatric solid tumors and is discussed in the following section.
The miR-17~92 Cluster is a Downstream Effector of 
Oncogenic Transcription Factors
The miR-17~92 cluster is expressed during normal development of 
the brain, heart, lungs, and immune system (Koralov et al., 2008; 
Ventura et al., 2008; Bian et al., 2013; Chen et al., 2013) and is known 
to regulate critical genes involved in cell growth, proliferation, 
and apoptosis. This cluster is comprised of six different miRNAs 
that are co-expressed, including miR-17, miR-18a, miR-19a, 
miR-19b-1, miR-20a, and miR-92-1. Dysregulation of the miR-17~92 
cluster has been shown in several pediatric solid tumors 
including neuroblastoma, Wilms tumor, retinoblastoma, and 
osteosarcoma, where a higher expression generally correlates 
with a poorer prognosis (Chen and Stallings, 2007; Baumhoer 
et al., 2012; Li et al., 2014). The miR-17~92 cluster is particularly 
interesting due to its regulation by the transcription factor MYC 
and its homologue MYCN, where it seems to act as a mediator 
for some of MYC/MYCN’s oncogenic effects (Schulte et al., 
2008). Other transcription factors known to target the miR-
17~92 cluster include members of the E2F family and STAT3 
(Mogilyansky and Rigoutsos, 2013).
Several studies have demonstrated that the miR-17~92 cluster 
regulates many downstream components of the transforming 
growth factor beta (TGF-β) pathway, which is known to 
participate in a variety of cellular process such as differentiation, 
proliferation, and immune cell activation. A study by Fontana 
et al. (2008) demonstrated that in neuroblastoma, miR-17 and 
miR-20a downregulate the cyclin-dependent kinase inhibitor 
p21, which is activated by TGF-β. p21 plays a key role in the 
inhibition of cell cycle progression by blocking the transition 
from G1 to S phase, and its deregulation leads to uncontrolled 
cell growth. Additionally, Fontana et al. (2008) showed that miR-
17-5p regulated another downstream component of TGF-β, 
the pro-apoptotic factor Bcl-2 interacting mediator (BIM). 
Mestdagh et al. (2010) later investigated miR-17~92 regulation 
of the TGF-β pathway in more depth and identified miR-17 and 
miR-20a as regulators of TGFBR2 and miR-18a as a regulator 
of SMAD2 and SMAD4, both signal transducers for TGF-β 
receptors. miR-18a and miR-19a have also been shown to repress 
estrogen receptor (ESR1) expression, and prolonged knockdown 
of miR-18a induced morphological differentiation of SK-N-BE 
neuroblastoma cells. Interestingly, the TGF-β pathway interacts 
with ESR1 signaling via several of the SMADs (Band and Laiho, 
2011), suggesting a complex interplay between miR-17~92 and 
its targeted pathways necessary for fine-tuning differentiation 
during neuronal development—a balance that is disrupted 
when miR-17~92 is overexpressed. While no studies have 
investigated in detail the interaction between the miR-17~92 
cluster and TGF-β pathway in Wilms tumor, the TGF-β pathway 
has been implicated in Wilms tumor development. In contrast 
with neuroblastoma, the TGF-β pathway appears to function as 
a promoter of Wilms tumor progression, and TGF-β is highly 
expressed in primary tumors, even more so in metastatic tumors. 
This multifaceted behavior of the TGF-β pathway has been 
shown in other cancers and implies that the pathway’s influence 
is specific to the tumor it is activated in.
The E2F family of transcription factors serve an important 
role in cell cycle control as their expression can cause cells to 
enter the G1 phase to initiate cell division (Chen et al., 2009). 
Several members, including E2F1, E2F2, and E2F3, all regulate 
miR-17~92 expression. In a study by Kort et al. (2008) a member 
of the E2F family of transcription factors, E2F3, was shown to 
be exclusively expressed in Wilms tumor and not in other types 
of kidney tumors. In line with this, they compared expression 
of the miR-17~92 miRNAs in Wilms tumor samples to other 
renal tumor subtypes and found them all to be upregulated. They 
were also able to show a correlation between E2F3 expression 
and the stage of Wilms tumor, where it was highest in late-stage 
metastatic tissues. In retinoblastoma, an early study investigating 
the miR-17~92 cluster identified that one of its members, miR-
20a, participates in an autoregulatory feedback loop with E2F2 
and E2F3 (Sylvestre et al., 2007), as they found both transcription 
factors are themselves downregulated by miR-20a. The authors 
suggested that this autoregulation was critical in preventing 
expression of excessive amounts of E2F transcription factors. 
Given that MYC/MYCN and E2F have previously been shown 
to induce each other’s expression, miR-20a appears to play an 
important role in keeping this positive feedback loop in check 
(Leone et al., 1997; Strieder and Lutz, 2003). Therefore, it is easy 
to see how disruption in one or more of these regulatory elements 
could lead to uncontrolled expression of these proliferative and 
anti-apoptotic signals.
A later study by Conkrite et al. (2011) investigated miR-17~92 
in retinoblastoma and revealed that this cluster was capable of 
driving retinoblastoma formation in RB1/p107-deficient mice. 
RB1 plays a key role in inhibiting cell cycle progression, and 
germline mutations of this gene can lead to familial retinoblastoma 
formation (Friend et al., 1986; Classon and Harlow, 2002). 
RB1’s protein product, pRB, inhibits E2F transcription factors 
by binding and inactivating them, and its absence enables 
miR-17~92–driven tumor formation.
The miR-17~92 cluster also plays a role in driving tumor 
progression and metastasis in osteosarcoma (Li et al., 2014). A 
recent study by Yang et al. (2018) identified QKI2 as a regulatory 
target of the miR-17~92 cluster. QKI proteins have previously 
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been shown to inhibit β-catenin and induce differentiation 
in colon cancer. Yang at el. demonstrated that miR-17~92 
downregulated QKI2, causing upregulation of β-catenin, 
leading to increased proliferation, invasion, and migration in 
osteosarcoma (Yang et al., 2018). Additionally, miR-20a has 
previously been shown to downregulate Fas expression, which 
is a cell surface marker that interacts with FasL to induce 
apoptosis in the lungs, where osteosarcoma almost exclusively 
metastasizes to (Huang et al., 2012).
The miR-17~92 cluster plays a tumorigenic role in a number 
of pediatric solid tumors including neuroblastoma, Wilms 
tumor, retinoblastoma, and osteosarcoma. The use of the 
miRNA pathway by transcription factors such as the MYC and 
E2F families enables them to target a wide range of genes and 
immediately effect gene expression at the post-transcriptional 
level. Continued research into how miRNAs may operate as 
oncogenic drivers will likely expand the repertoire of potential 
drug targets available to us.
Let-7 Dysregulation is a Feature in Many Pediatric 
Solid Tumors
The let-7 family of miRNAs are among the most well-characterized 
tumor suppressors due to their frequent downregulation in 
cancers. In total, there are 12 members of the let-7 family located 
across eight different chromosomes; however, in most cells, only 
a selection of these miRNAs will be expressed (Balzeau et al., 
2017). let-7 miRNAs are important in regulating the cell cycle 
and maintaining cells’ differentiated state by targeting a wide 
range of genes with known roles in cancer biogenesis such as 
MYC/MYCN, RAS, CDK6, and HMGA2 (Buechner et al., 2011; 
Wu et al., 2015).
let-7 is regulated by the LIN28 proteins, LIN28A and LIN28B, 
which mediate uridylation, prevent processing of the let-7 
precursor, and are important for maintaining pluripotency in 
cells (Lehrbach et al., 2009; Balzeau et al., 2017). Both Lin28 genes 
contain let-7 target sites and participate in a double-negative 
feedback loop with let-7 (Yin et al., 2017). Overexpression of 
Lin28 tends to drive cells towards oncogenesis and is a common 
feature in cancers. In a study by Urbach et al. (2014), Lin28b 
overexpression was found in approximately 30% of Wilms 
tumors. Additionally, they found overexpression of Lin28 
could induce tumor formation in specific renal intermediates 
and that restoration of let-7 activity could reverse this effect 
in mice. Similar examples have been shown in mouse models, 
where Lin28b overexpression can drive hepatoblastoma and 
hepatocellular carcinoma in the liver and neuroblastoma in 
the neural crest (Molenaar et al., 2012; Nguyen et al., 2014). 
Molenaar et al. (2012) investigated Lin28b in neuroblastoma and 
demonstrated that Lin28b could enhance MYCN protein levels 
via let-7 regulation. However, a later study by Powers et al. (2016) 
showed that Lin28b expression was redundant in certain MYCN-
amplified neuroblastoma cells, as overexpression of the MYCN 
transcript could function as a miRNA sponge for let-7, thereby 
negating their effect regardless of expression level. Powers et al. 
showed that most neuroblastomas were characterized by a loss 
of let-7 with either MYCN overexpression or chromosomal 
loss of arm 3p or 11q, where several let-7 miRNAs are located 
(Figure 1A). The authors noted that these events were generally 
mutually exclusive and suggested that the presence of one event 
alleviated selective pressure for the other. 
A study by Di Fiore et al. (2016) revealed that let-7d could 
promote and suppress tumor formation within the same 
system. In this study, they found that let-7d overexpression in 
osteosarcoma cells reduced several stemness genes, including 
Lin28b, HMGA2, Oct3/4, and SOX2, and could elicit the 
mesenchymal-to-epithelial transition with upregulation of 
the epithelial marker E-cadherin and downregulation of 
mesenchymal markers N-cadherin and vimentin. However, they 
also found that let-7d enhanced cell migration and invasion, 
presumably by acting via the TGF-β pathway, which is known 
to promote this behavior. let-7d strongly increased versican VI 
expression, which has previously been shown to activate the 
TGF-β pathway in osteosarcoma (Li S. et al., 2014).
In Ewing sarcoma, Hameiri-Grossman et al. (2015) found 
that let-7 downregulated the Ras oncogene, as well as the 
transcription factor HIF-1a, to reduce EWS-FLI-1 expression 
(Figure 1B). EWS-FLI-1 is a hybrid transcript that results from 
a translocation event involving EWS and FLI1, and translocation 
events such as this are present in nearly all Ewing sarcoma cases 
and are believed to drive the disease (Delattre et al., 1994).
Loss of Let-7 plays a key role in many pediatric solid tumors 
as its loss enables expression of transcription factors and other 
genes that participate in oncogenesis. This has been emphasized 
in neuroblastoma, where it has been suggested that loss of let-7 
function is an essential event in tumor development and positions 
the miRNA pathway as a central player in pediatric solid tumors.
miR-9 Has Been Shown to Play Oncogenic 
and Tumor-Suppressive Roles in Different 
Pediatric Tumors
miR-9 is a highly conserved miRNA involved in several different 
cellular processes including cell proliferation, differentiation, and 
migration. Early studies revealed miR-9 to be highly expressed 
in the brain and play a role both during development and in 
the adult brain; however, miR-9 has also been associated with 
many cancers outside the brain, acting as an oncogene or tumor 
suppressor (Coolen et al., 2013). Mir-9 is upregulated by MYC/
MYCN and plays a role in promoting tumor growth and metastasis 
in several cancers including breast cancer, osteosarcoma, and 
rhabdomyosarcoma, where it is often overexpressed (Iorio 
et al., 2005; Luo et al., 2017) However, in other cancers such as 
neuroblastoma, miR-9’s role is less clear, and studies have argued 
for oncogenic and tumor suppressor functions (Laneve et al., 
2007; Zhi et al., 2014).
The role of miR-9 in osteosarcoma appears to be in promoting 
cell growth and metastasis (Zhu et al., 2015; Qi et al., 2016). In 
a study by Zhu et al. (2015), miR-9 knockdown suppressed cell 
growth and migration of osteosarcoma cells. They were also 
able to show that miR-9 downregulated RB1 via the Grap2 
and cyclin D interacting protein (GCIP), thereby promoting 
E2F-mediated cell division (Figure 1C). Similar behavior has 
been observed in the alveolar subtype of rhabdomyosarcoma, 
where miR-9 contributes to increased cell proliferation and 
migration (Missiaglia et al., 2017). In this study by Missiaglia 
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et  al. (2017), miR-9 was shown to be induced by the PAX3/
FOXO1 fusion gene via MYCN, which is specific to this subtype 
of rhabdomyosarcoma.
In neuroblastoma, miR-9 expression has been shown to be 
both up- and downregulated in different studies. An early study 
by Laneve et al. (2007) showed that miR-9 was downregulated 
in 50% of primary neuroblastoma samples, and follow-up 
experiments demonstrated that miR-9 could act together 
with miR-125a and miR-125b to suppress cell proliferation by 
targeting a truncated isoform of the neurotrophin receptor 
tropomyosin-related kinase C (trkC) (Figure 1D). However, 
a later study by Ma et al. (2010) found miR-9 to be a target of 
MYCN and that miR-9 expression correlated with MYCN and 
metastatic status in neuroblastoma tumors. In this same study 
(albeit in breast cancer cells), Ma et al. also demonstrated that 
miR-9 suppressed E-cadherin to activate β-catenin and promote 
the epithelial-to-mesenchymal transition. Mir-9 is frequently 
involved in promoting cell migration; however, its absence has 
also been shown to produce different responses such as cell cycle 
arrest or apoptosis in neurons depending on their origin (Bonev 
et al., 2011). The contradictory behavior seen with studies of 
miR-9 highlight the diverse roles that individual miRNAs can 
play, and more comprehensive studies are needed to identify the 
relevant contextual influences on miRNA behavior.
miR-34 Is a Key Regulator of the Cell Cycle and 
Drug Resistance in Pediatric Solid Tumors
The miR-34 family has garnered significant interest since 
its members were discovered to be direct transcriptional 
targets of the tumor suppressor and transcription factor p53 
(Hermeking, 2010). The miR-34 family consists of three 
miRNAs encoded by two genes, mir-34a and mir-34b/c. All 
three miRNAs play a key role in regulating apoptosis and 
the cell cycle by inducing G1 phase arrest. One of the more 
interesting facts about miR-34a and miR-34b/c is their genomic 
locations, which are located on chromosomes 1p36 and 11q23, 
respectively, regions that are frequently lost in pediatric solid 
tumors (Ruteshouser et al., 2005; Wittmann et al., 2007). In 
particular, loss of 1p36 occurs in 20–30% of neuroblastoma 
cases and correlates with MYCN amplification (Caron et al., 
1993; Maris et al., 1995), whereas loss of 11q23 in occurs in 
approximately 40% of cases but almost never occurs with 
MYCN amplification (Figure 1A) (Guo et al., 1999; Attiyeh 
et al., 2005). miR-34 members are also regulators of the MYC 
family, as miR-34a is known to regulate MYCN and miR-34b 
and mir-34c to regulate c-MYC (Wei et al., 2008).
Studies on mir-34a expression have identified frequent 
downregulation in neuroblastoma, osteosarcoma, and 
hepatoblastoma (Jiao et al., 2016). miR-34a is itself considered 
a tumor suppressor due to its involvement in cell cycle arrest 
and apoptosis (De Antonellis et al., 2014). In neuroblastoma, 
Cole et  al. (2008) investigated the growth-inhibitory effects 
of several miRNAs mapping to common chromosomal 
aberrations by overexpressing them in cell lines. In most 
cases, overexpression did not lead to a noticeable change 
in phenotype; however, miR-34a and miR-34c induced 
significant growth inhibition in cell lines with 1p36 deletion. 
Growth inhibition and suppression of metastasis by miR-34a 
have also been shown in osteosarcoma by several studies, 
where members of key proliferative signal transduction 
pathways such as c-Met, DUSP1, and Eag1 were identified as 
regulatory targets (Yan et al., 2012; Wu X. et al., 2013; Gang 
et al., 2017). The miR-34 family also targets several members 
of the Notch signaling pathway, which has been linked to 
both oncogenic and tumor-suppressive roles depending 
on the cellular context. In osteosarcoma, activation of the 
Notch pathway is known to contribute to tumor growth, and 
miR-34a–mediated downregulation of this pathway likely 
contributes to its tumor-suppressive role. However, in Ewing 
sarcoma, a recent study investigating miR-34b suggested 
that it could act as an oncogene, promoting proliferation, 
migration, and invasion through Notch1 repression (Lu Q. et 
al., 2018). Prior studies have shown correlations between high 
mir-34a expression and patient survival, which would indicate 
a tumor-suppressive role for mir-34a (Nakatani et  al., 2012; 
Marino et al., 2014). It is unclear why miR-34a and miR-34b 
would display contrasting effects given their shared targets, 
and further investigation is needed.
Several studies by Pu et al. (2016) and Pu et al. (2017) have 
suggested that miR-34a may also play a role in promoting 
multidrug resistance in osteosarcoma. In these studies, they 
found that miR-34a-5p enhanced multidrug resistance through 
downregulation of the CD117 and AGTR1 genes in vitro. CD117 is 
often highly expressed in drug-resistant tumors and is commonly 
used as a marker for stemness (Adhikari et al., 2010). In contrast, 
Nakatani et al. found that miR-34a increased chemosensitivity in 
Ewing sarcoma (Nakatani et al., 2012).
Other miRNAs Involved in Multiple Pediatric 
Solid Tumors
A substantial number of other miRNAs have been discovered 
with functional implications in multiple pediatric solid tumors. 
One such miRNA is miR-125b, which typically exhibits tumor-
suppressive properties in cancers such as neuroblastoma, 
osteosarcoma, and Ewing sarcoma, where it is commonly 
dysregulated (Laneve et al., 2007; Li J. et al., 2014; Xiao et al., 
2019). Previously, it was mentioned that miR-125b participates 
in a network with miR-125a and miR-9, regulating expression 
of a truncated trkC isoform to control neuroblastoma growth 
and differentiation (Laneve et al., 2007; Le et al., 2009). 
In osteosarcoma, miR-125b was found to regulate STAT3 
by downregulating MAP kinase kinase 7 (MKK7), which 
inactivates STAT3 via dephosphorylation (Xiao et al., 2019). 
Loss of miR-125b and consequent overexpression of MKK7 
led to increased tumor formation and poorer prognosis. In 
Ewing sarcoma, miR-125b is involved in regulating the PI3K 
signaling pathway; could inhibit cell proliferation, migration, 
and invasion; and induce apoptosis through suppression of 
PIK3CD (Li J et al., 2014). Conversely, in retinoblastoma, miR-
125b is overexpressed and has shown oncogenic properties 
by promoting cell proliferation and migration and inhibiting 
apoptosis (Bai et al., 2016). Conflicting behavior with miR-125b 
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has been observed in many other cancers, which suggests that 
its role is highly dependent on cell identity (Sun et al., 2013).
miR-124 has been widely reported to act as a tumor suppressor 
by inhibiting cell growth and metastasis and acts as a key mediator 
of differentiation in several pediatric solid tumors (Peng et al., 
2014; Feng et al., 2015; Zhao et al., 2017). In neuroblastoma, miR-
124a increased the proportion of differentiated cells possessing 
neurite outgrowths (Le et al., 2009). In retinoblastoma, miR-124 
participates in a regulatory network with lncRNAs Malat1 and 
XIST, which both function as oncogenes by enhancing growth 
and metastasis through downregulation of miR-124 (Liu S. 
et al., 2017; Hu et al., 2018). miR-124 itself was shown to target 
STAT3 to inhibit cell proliferation, migration, and invasion 
(Liu S. et  al., 2016). In Ewing sarcoma, miR-124 expression is 
suppressed, and expression was found to reduce growth and 
metastasis via downregulation of mesenchymal genes such 
as SLUG and cyclin D2 (CCND2) (Li et al., 2017). Finally, in 
osteosarcoma, retinoblastoma, and Ewing sarcoma, miR-143 
has been found to be dysregulated (De Vito et al., 2012; Li S. 
et  al., 2014; Wang et al., 2016; Sun et al., 2018). For example, 
Li et  al. investigated miR-143 function in osteosarcoma and 
showed that miR-143 participated in the TGF-β pathway by 
targeting versican, and TGF-β could reduce miR-143 expression 
to promote cell migration and invasion (Li S. et al., 2014). FOS-
like antigen 2 (FOSL2) was also identified as a miR-143 target, 
which enhanced cell proliferation, migration, and invasion in 
the absence of miR-143 (Sun et al., 2018). Additional miRNA 
studies have been listed in Table 1.
TABLE 1 | miRNAs that have been shown to exhibit oncogenic or tumor-suppressive effects through functional studies in various pediatric solid tumors.
Cancer Oncogenic miRNAs/clusters Comments 
Neuroblastoma mir-15 (Xin et al., 2013), mir-17~92 (Fontana et al., 2008; Loven et al., 2010; Mestdagh et al., 
2010), miR-93 (Chakrabarti et al., 2012), miR-380 (Swarbrick et al., 2010), miR-558 (Shohet et al., 
2011; Qu et al., 2015)
mir-17~92 dysregulation is 
common in MYCN-amplified 
neuroblastomas.
Osteosarcoma let-7d (Di Fiore et al., 2016), miR-9 (Zhu et al., 2015; Qi et al., 2016), miR-17~92 (Huang et al., 
2012; Li X. et al., 2014; Lu et al., 2018a; Yang et al., 2018b), miR-34a (Pu et al., 2016; Pu et al., 
2017), miR-214 (Rehei et al., 2018)
Retinoblastoma miR-17~92 (Conkrite et al., 2011; Nittner et al., 2012; Jo et al., 2014), miR-125b (Bai et al., 2016) Loss of RB1 function may enable 
mir-17~92–mediated oncogenicity.
Wilms tumor miR-19b (Liu G.-L. et al., 2017), miR-483 (Veronese et al., 2010; Liu M. et al., 2013), miR-1180 
(Jiang and Li, 2018)
Hepatoblastoma miR-492 (von Frowein et al., 2018)
Ewing sarcoma mir-17~92 (Schwentner et al., 2017), miR-20b (Kawano et al., 2017), miR-34b, b (Lu et al., 2018b) 
miR-130b (Satterfield et al., 2017)
EWS-FLI-1 may upregulate mir-
17~92 and miR-34b.
Cancer Tumor-suppressive miRNAs/clusters Comments
Neuroblastoma let-7 (Buechner et al., 2011; Molenaar et al., 2012; Hennchen et al., 2015; Powers et al., 2016), 
mir-7-1 (Chakrabarti et al., 2012), mir-9 (Laneve et al., 2007), mir-10 (Foley et al., 2011), miR-34a 
(Welch et al., 2007; Cole et al., 2008; Tivnan et al., 2011), miR-34c (Cole et al., 2008), miR-101 
(Buechner et al., 2011), miR-124a (Le et al., 2009), miR-125 (Laneve et al., 2007; Le et al., 2009), 
miR-145 (Zhang et al., 2014), miR-184 (Chen and Stallings, 2007; Foley et al., 2010; Tivnan et al., 
2010), miR-193b (Roth et al., 2018), miR-202 (Buechner et al., 2011), miR-203 (Zhao et al., 2015), 
miR-449 (Buechner et al., 2011), miR-542 (Bray et al., 2011), miR-584 (Xiang et al., 2015), miR-591 
(Shohet et al., 2011)
let-7 and mir-34 are regulators of 
the MYCN oncogene.
Osteosarcoma let-7d (Di Fiore et al., 2016), miR-1 (Novello et al., 2013), miR-34 (Yan et al., 2012; Wu et al., 2013b; 
Gang et al., 2017; Wen et al., 2017), miR-125b (Le et al., 2009; Xiao et al., 2019), miR-133b 
(Novello et al., 2013), miR-134 (Thayanithy et al., 2012), miR-138 (Zhu et al., 2016), miR-143 (Li 
et al., 2014c; Sun et al., 2018), miR-195 (Han et al., 2015), miR-223 (Dong et al., 2016), miR-363 
(Wang K. et al., 2018), miR-369 (Thayanithy et al., 2012), miR-382 (Thayanithy et al., 2012), miR-
451 (Yuan et al., 2015), miR-454 (Niu et al., 2015), miR-485 (Du et al., 2018), miR-544 (Thayanithy 
et al., 2012), miR-590 (Wang W.T. et al., 2018), miR-708 (Chen and Zhou, 2018), miR-2682 (Zhang 
et al., 2018b)
miR-34 suppresses tumor growth 
in osteosarcoma but may also 
contribute to drug resistance.
Retinoblastoma miR-101 (Lei et al., 2014), miR-124 (Liu S. et al., 2016), miR-143 (Wang et al., 2016) STAT3 is a target of miR-124.
Rhabdomyosarcoma miR-1 (Rao et al., 2010; Li et al., 2012), mir-22 (Bersani et al., 2016), miR-29 (Li et al., 2012), miR-
133a (Rao et al., 2010), miR-206 (Li et al., 2012; Missiaglia et al., 2010)
miR-1 appears to play a key role in 
differentiation of several sarcomas.
Wilms tumor let-7 (Urbach et al., 2014), miR-16 (Chen W. et al., 2018), miR-34a (Chen W. et al., 2018), mir-92a 
(Zhu et al., 2018b), miR-613 (Wang et al., 2017a)
miR-92a was shown to act as a 
tumor suppressor unlike what is 
observed in other pediatric solid 
tumors.
Hepatoblastoma miR-26 (Zhang et al., 2018d) miR-26 was shown to repress 
LIN28B in hepatoblastoma.
Ewing sarcoma let-7 (Hameiri-Grossman et al., 2015; Kawano et al., 2015), miR-16 (Kawano et al., 2015), miR-22 
(Parrish et al., 2015), miR-29b (Kawano et al., 2015), miR-30a (Franzetti et al., 2013), miR-30d (Ye 
et al., 2018), miR-31 (Karnuth et al., 2014), miR-34a (Nakatani et al., 2012; Ventura et al., 2016), 
miR-124 (Li et al., 2017), miR-125b (Li et al., 2014b), miR-143 (De Vito et al., 2012), miR-145 (Riggi 
et al., 2010; De Vito et al., 2012), miR-185 (Zhang et al., 2018c), miR-193b (Moore et al., 2017), 
miR-708 (Robin et al., 2012)
Several miRNAs such as let-7 and 
miR-145 are downregulated by 
EWS-FLI-1.
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miRNAs Regulate All Aspects of Tumorigenesis
Widespread dysregulation of miRNAs is observed in 
many pediatric solid tumors, and functional studies have 
demonstrated that many of these miRNAs can drive or repress 
oncogenic pathways responsible for cell proliferation, apoptosis, 
angiogenesis, metastasis, and drug resistance. Importantly, 
miRNAs such as let-7 and miR-34 play a vital role in pediatric 
solid tumors by regulating established oncogenic transcription 
factors such as the MYC and E2F families (Wei et al., 2008; 
Buechner et al., 2011). Other miRNAs, such as the miR-17~92 
cluster and miR-9, serve as downstream effectors for these 
transcription factors, although their exact role in tumorigenesis 
seems to depend on the overall transcriptional landscape 
(Schulte et al., 2008; Ma et al., 2010). In some cases, viewing 
miRNAs as oncogenes or tumor suppressors likely represents 
an oversimplification of their role in cancer, and a better 
understanding of their participation in oncogenic networks will 
be needed to clarify their exact contributions.
LONG NON-CODING RNAS REGULATE 
ONCOGENIC PATHWAYS IN PEDIATRIC 
SOLID TUMORS
For a long time, it was believed that the human genome was 
mostly comprised of “junk” DNA, despite pervasive transcription 
of much of the genome outside of protein-coding genes and 
other known RNAs at the time (Prensner and Chinnaiyan, 2011). 
Originally thought of as transcriptional noise, lncRNAs have now 
emerged as functional regulators of nearly all essential cellular 
processes including growth, differentiation, cell state maintenance, 
apoptosis, splicing, and epigenetic regulation. The first lncRNA, 
H19, was discovered in 1990 where an RNA molecule was found 
spliced and polyadenylated in a manner typical of mRNAs; 
however, it lacked an open reading frame and was believed to 
function as an untranslated RNA molecule (Brannan et al., 1990).
Often, lncRNAs participate within protein complexes and 
can operate as scaffolds, guides, decoys, or allosteric regulators. 
Many lncRNAs function as epigenetic regulators by interacting 
with proteins involved in chromatin remodeling and DNA 
methylation. Frequently, these lncRNAs will be cis-acting and 
regulate the regions near their transcribed location; however, 
some are trans-acting. Other lncRNAs function as competing 
RNAs (ceRNAs), which contain miRNA binding sites in a similar 
manner to mRNAs in order to compete and reduce the activity 
of miRNAs.
Several studies have investigated lncRNA expression in pediatric 
tumors and have successfully identified unique expression profiles 
in different cancers and tumor subtypes (Mitra et al., 2012; Brunner 
et al., 2012; Dong et al., 2014; Sahu et al., 2018). For example, 
Dong et al. (2014) compared hepatoblastoma samples to normal 
liver tissue in patients and found 2,736 differentially expressed 
lncRNAs. A study by Pandey et al. (2014) found 24 lncRNAs that 
could distinguish low- and high-risk neuroblastoma tumors. In 
a more recent study, Sahu et al. (2018) identified 16 differentially 
expressed lncRNAs that could be used to predict event-free 
survival with greater accuracy than other commonly used clinical 
risk factors. Mechanistic studies into many of these lncRNAs have 
revealed that they frequently act as an additional layer of regulation 
within established oncogenic networks involving protein-coding 
genes and miRNAs. While the field of lncRNAs is still relatively 
young, many studies have emerged that suggest that lncRNAs are 
far more integrated into existing gene networks than what has 
previously been appreciated (Figure 1). In the following section, 
the roles of some of the better-characterized lncRNAs in pediatric 
solid tumors will be discussed.
Malat1 Is Induced by MYCN in 
Neuroblastoma and Competes With 
Many miRNAs
One of the earliest lncRNAs to be associated with disease was 
Malat1 (metastasis-associated lung adenocarcinoma transcript 
1), which was shown to associate with metastatic tumors in 
non–small cell lung cancer patients (Ji et al., 2003). Malat1 is 
abundantly expressed and highly conserved across species, 
unlike many other lncRNAs, and displays remarkably diverse 
functions in cellular processes including alternative splicing, 
nuclear organization, and epigenetic modulation. Studies have 
suggested an important role for Malat1 in brain development, 
as it is highly expressed in neurons and its depletion has been 
shown to affect synapse and dendrite development (Bernard 
et al., 2010; Chen et al., 2016). However, its importance has been 
questioned as other studies have found that Malat1-KO mice are 
viable with no discernable change in phenotype (Nakagawa et al., 
2012; Zhang et al., 2012).
In addition to lung cancer, Malat1 is known to contribute 
to metastasis in other common types of cancer including 
hepatocellular carcinoma and bladder cancer, with evidence 
that it acts through induction of the epithelial-to-mesenchymal 
transition (Ying et al., 2012; Li G. et al., 2014; Yang et al., 2017). The 
role of Malat1 in several pediatric cancers has also been explored 
in recent studies. In neuroblastoma, Tee et al. (2014) recently 
identified a regulatory network involving N-Myc, Malat1, and the 
histone demethylase JMJD1A. They found that N-Myc upregulated 
JMJD1A via direct binding of its promoter region and that JMJD1A 
could demethylate histone H3K9 near the promoter region of 
Malat1, leading to its upregulation. MYCN-mediated upregulation 
of Malat1 provides one mechanism in which its amplification can 
lead to increased metastasis in neuroblastoma patients. Another 
study by Bi et al. (2017) also demonstrated that Malat1 regulated 
Axl expression, a transmembrane receptor tyrosine kinase, which is 
known to activate pathways involved in cell proliferation, survival, 
and migration. In osteosarcoma, Dong et al. (2015) demonstrated 
that Malat1 was highly expressed and could activate the PI3K/Akt 
pathway to promote proliferation and invasion.
Malat1 is known to interact with many miRNAs implicated in 
cancer. In osteosarcoma, several studies have shown Malat1 can 
function as a ceRNA for different miRNAs (Wang et al., 2017b; 
Liu K. et al., 2017b; Sun and Qin, 2018). miR-140-5p is a tumor 
suppressor that downregulates HDAC4, a histone deacetylase that 
contributes to tumorigenesis, and competitive binding by Malat1 
with miR-140-5p was shown to increase HDAC4 activity (Sun 
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and Qin, 2018). Malat1 was also shown to compete with miR-
144-3p binding to ROCK1/ROCK2, promoting proliferation and 
metastasis (Wang et al., 2017b). In a similar manner, Liu K. et al. 
(2017) found that Malat1 could regulate cell growth through 
high-mobility group protein B1 (HMGB1) via ceRNA activity 
with miR-142-3p and miR-129-5p. Finally, in retinoblastoma, 
Malat1 downregulated miR-124 activity, leading to activation of 
the transcription factor SLUG, which is also targeted by miR-124 
(Liu S. et al., 2017). SLUG has a known role in the epithelial-
to-mesenchymal transition by suppressing E-cadherin via the 
Wnt/B-catenin pathway (Prasad et al., 2009). 
In addition to interactions with miRNAs, Malat1 has also 
been shown to be processed directly by the Drosha–DGCR8 
microprocessor complex through binding sites in the 5’ end of the 
transcript (MacIas et al., 2012). lncRNAs such as Malat1 cooperate 
with the miRNA pathway and a number of transcription factors 
and epigenetic factors to form a complex network responsible 
for regulating tumorigenesis. The capacity for Malat1 to drive 
proliferation and metastasis in pediatric solid tumors suggests 
that dysregulation of any of these regulatory components can be 
sufficient for the development of cancer and highlights the value 
of further research into the relatively new field of lncRNAs.
H19: lncRNA Dysregulation via Loss 
of Imprinting may Contribute to 
Tumorigenesis
H19 is a paternally imprinted gene that is typically expressed 
exclusively from the maternal allele. Early reports suggested 
that H19 functioned as a tumor suppressor capable of inhibiting 
cell growth (Hao et al., 1993; Zhang et al., 1993; Casola et  al., 
1997; Fukuzawa et al., 1999). Studies in childhood solid 
tumors such as hepatoblastoma, Wilms tumor, and embryonic 
rhabdomyosarcoma supported this idea, as all three cancers often 
exhibited reduced H19 expression and had frequently lost the 
maternal 11p15 chromosomal region housing this gene (Fukuzawa 
et al., 1999). Other studies, in osteosarcoma and retinoblastoma, 
suggested an oncogenic role for H19, as its upregulation and 
loss of imprinting were commonly seen (Chan et al., 2014; Li 
L. et al., 2018). This observation was also seen in many other 
cancers including breast cancer (Lottin et al., 2002). Recently, the 
Hedgehog signaling pathway, a regulator of differentiation known 
to participate in cancer development and metastasis, was shown 
to induce H19 expression (Chan et al., 2014). 
Understanding the exact function of H19 has proved difficult; 
however, it was known to sit downstream of the insulin growth 
factor 2 (IGF2) gene, a growth factor known to play a role in 
tumorigenesis. Early reports suggested interactions between 
IGF2 and H19, as loss of imprinting of either gene caused biallelic 
expression of the other gene (Ulaner et al., 2003). Ulaner et al. 
(2003) proposed a model for H19 and IGF2 involving a CCTF-
binding site seated between the two genes, which could facilitate 
the blocking of IGF2 or transcription of H19 depending on its 
methylation status. However, this model suggested that H19 may 
simply serve as a marker for epigenetic disruptions and left open 
the question of what H19’s actual function is.
More recent studies have demonstrated a role for H19 in 
epigenetic regulation. H19 binds to several epigenetic regulators 
including S-adenosylhomocysteine hydrolase (SAHH), methyl-
CpG–binding domain protein 1 (MBD1), and enhancer of zeste 
homolog 2 (EZH2) (Raveh et al., 2015; Zhou et al., 2015). H19 
was found to inhibit SAHH, which led to downregulation of 
DNMT3B-mediated methylation. MBD1 binds methylated DNA 
and recruits other proteins to mediate transcriptional repression 
or histone methylation, and H19 was shown to recruit this 
protein to several genes including IGF2 (Monnier et al., 2013). 
Finally, EZH2 is a histone methyltransferase that forms part of 
the Polycomb repressive complex 2 (PRC2) (Sauliere et al., 2006; 
Zhou et al., 2015).
H19 also plays a role in maintaining cells in an undifferentiated 
state by associating with the KH-type splicing regulatory protein 
(KSRP). When multipotent mesenchymal cells were induced, 
H19 was found to dissociate with KSRP to promote several of its 
functions including the decay of unstable mRNAs and increasing 
the expression of specific miRNAs involved in proliferation and 
differentiation though association with Drosha and Dicer. 
H19’s role in cancer has been emphasized by studies 
highlighting its relationship to the tumor suppressor p53. The 
H19 locus reciprocally regulates p53, as p53 suppresses H19 
transcription and H19 can inactivate p53 by directly interacting 
with it (Yang et  al., 2012). Notably, H19 also encodes for a 
miRNA in its first exon, miR-675, which suppresses p53 and 
several other targets including Rb, Igf1r, and several SMAD and 
cadherin genes. In the absence of functional p53, H19 was shown 
to promote tumor proliferation and survival under hypoxic 
conditions. Later studies in colorectal cancer showed that H19 
could induce EMT by acting as a ceRNA (Liang et al., 2015). 
ceRNA function has recently been shown in a retinoblastoma 
study, targeting the mir-17~92 cluster (Zhang A. et al., 2018a). 
In this study, they found that H19 contained seven functional 
binding sites for mir-17~92 and was able to sponge mir-17~92 
activity. This led to a de-repression of genes such as p21 and 
STAT3 targets BCL2, BCL2L1, and BIRC5.
In a review by Raveh et al. (2015) it was proposed that H19 
may behave differently in a manner that was dependent on 
the developmental stage of the cell, which could explain the 
evidence suggesting both oncogenic and tumor-suppressive 
roles. Here, the authors found that H19 functioned as a 
promoter of differentiation during the embryonic period and 
that absence of H19 at this stage could leave cells vulnerable to 
forming cancer, thereby seemingly acting as a tumor suppressor. 
However, in adult cells, where it is not normally expressed, H19 
could function as an oncogene by promoting tumor survival 
and metastasis (Matouk et al., 2015).
TUG1 Regulates Transcription  
Factors Through Competition  
With miRNAs in Osteosarcoma
Recent studies have investigated the role of lncRNA TUG1 as a 
prognostic factor and ceRNA in osteosarcoma. Ma et al. (2016) 
identified a correlation between upregulation of TUG1 and poor 
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prognosis and metastasis, which was also evident in plasma, 
and suggested a potential use as a biomarker for patients with 
osteosarcoma. TUG1 is known to act through ceRNA activity 
against a number of miRNAs including miR-9, miR-132, miR-
144, miR-153, miR-212, and miR-335 (Xie et al., 2016; Cao 
et  al., 2017; Wang et al., 2017a; Li G. et al., 2018; Li H. et al., 
2018). These miRNAs are known to regulate pathways involved 
in proliferation, cell cycle control, migration, and apoptosis. 
For example, TUG1 was shown to mediate de-repression of 
the transcription factor POU class 2 homeobox1 (POU2F1) via 
downregulation of mir-9 (Figure 1E) (Xie et al., 2016). POU2F1 
itself participates in various cellular processes including growth, 
metabolism, stem cell identity, and metastasis (Vázquez-Arreguín 
and Tantin, 2016). In another example by Cao et al. (2017) they 
found that TUG1 also regulates migration and the epithelial-to-
mesenchymal transition via ceRNA action on miRNA-144-3p. 
miR-144-3p is a regulator of EZH2, and upregulation of EZH2 
induced cell migration through the Wnt/β-catenin pathway (Cao 
et al., 2017). Studies have also demonstrated direct interactions 
between TUG1 and the Polycomb repressor complex; however, 
to our knowledge, this has not been investigated in pediatric 
solid tumors (Yang et al., 2011).
Other Long Non-Coding RNAs in Pediatric 
Solid Tumors
In addition to those mentioned above, there are a number of 
other lncRNAs that have been identified as potential oncogenes 
or tumor suppressors involved in the pathogenesis of pediatric 
solid tumors (see Table 2) (Chen et al., 2017; Pandey et al., 2015).
For example, in osteosarcoma, lncRNAs HOTAIR, SNHG16, 
SNHG12, THOR, PACER, MFI2, and HOTTIP have all been 
shown to promote tumor or cell growth (Li et al., 2016; Qian 
et al., 2016; Ruan et al., 2016; Yin et al., 2016; Chen W. et al., 2018; 
Su et al., 2019; Wang et al., 2019). HOTAIR is known to play a 
role in chromatin regulation by acting as a scaffold for PRC2 
and lysine-specific histone demethylase 1 (LSD1), and can also 
act as a ceRNA for miR-217 (Gupta et al., 2010; Tsai et al., 2010; 
Wang et al., 2019). SNHG16 has been shown to act as a ceRNA 
for several miRNAs including miR-205 and miR-340 (Zhu  C. 
et al., 2018; Su et al., 2019). Additionally, several lncRNAs 
are downregulated in osteosarcoma with potential tumor-
suppressive activity such as loc285194, MEG3, and TUSC7 (Pasic 
et al., 2010; Cong et al., 2016; Shi et al., 2018). loc285194 has been 
identified as a transcriptional target of p53 and can downregulate 
miR-211 (Liu Q. et al., 2013). In another study, increased p53 
TABLE 2 | lncRNAs that play a role in pediatric solid tumors. OS, osteosarcoma; RB, retinoblastoma; NB, neuroblastoma; WT, Wilms tumor; HB, hepatoblastoma; 
RMS, rhabdomyosarcoma; ES, Ewing sarcoma.
Long Non-coding RNA Cancer Cellular Functions References
Malat1 OS, RB, NB Upregulates—proliferation, survival, migration, 
invasion.
(Tee et al., 2014; Dong et al., 2015; Bi et al., 2017; 
Liu K. et al., 2017; Liu S. et al., 2017; Wang K. et al., 
2017; Sun and Qin, 2018)
H19 OS, RB, WT, HB, RMS Upregulates—proliferation, survival. Regulates 
cell fate/differentiation.
(Zhang et al., 1993; Casola et al., 1997; Fukuzawa 
et al., 1999; Chan et al., 2014; Matouk et al., 2015; 
Raveh et al., 2015; Li L. et al., 2018)
TUG1 OS Upregulates—proliferation, survival, migration. (Ma et al., 2016; Xie et al., 2016; Cao et al., 2017; 
Wang S. et al., 2017; Li G. et al., 2018; Li H. et al., 
2018)
HOTAIR OS, RB Upregulates—proliferation, survival, migration, 
invasion.
(Yang G. et al., 2018; Wang et al., 2019)
HOTTIP OS Upregulates—proliferation, resistance. (Li et al., 2016)
SNHG12 OS Upregulates—proliferation, migration. (Ruan et al., 2016)
SNHG16 OS Upregulates—proliferation, survival, migration, 
invasion.
(Su et al., 2019; Zhu et al., 2018a)
THOR OS, RB Upregulates—proliferation, migration. (Chen K.S. et al., 2018; Shang, 2018)
PACER OS Upregulates—proliferation, invasion. (Qian et al., 2016)
MFI2 OS Upregulates—proliferation, survival, migration, 
invasion.
(Yin et al., 2016)
loc285194 OS Downregulates—proliferation. (Pasic et al., 2010)
TUSC7 OS Downregulates—proliferation. (Cong et al., 2016)
MEG3 OS, RB Downregulates—proliferation, survival, 
invasion.
(Gao et al., 2017; Shi et al., 2018)
EWSAT1 OS, ES Upregulates—proliferation, metastasis. (Howarth et al., 2014; Sun et al., 2016)
XIST RB Upregulates—proliferation, survival. (Hu et al., 2018)
DANCR RB Upregulates—proliferation, migration, invasion. (Wang J. X. et al., 2018)
HOXA11-AS RB Upregulates—proliferation, survival. (Han et al., 2019)
PANDAR RB Upregulates—survival. (Sheng et al., 2018)
lncUSMYcN NB Upregulates—proliferation. (Liu et al., 2014; Liu S. et al., 2016)
NBAT-1 NB Downregulates—proliferation, invasion. 
Regulates cell fate/differentiation.
(Pandey et al., 2014)
CASC15-S NB Downregulates—proliferation, migration. (Russell et al., 2015)
LINC00473 WT Upregulates—proliferation, survival. (Zhu et al., 2018b)
CRNDE HB Upregulates—proliferation, angiogenesis. (Dong et al., 2017)
LINC01314 HB Downregulates—proliferation, migration. (Lv et al., 2018)
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expression and a decrease in cell proliferation and invasion 
were observed when MEG3 was overexpressed (Shi et al., 2018). 
Furthermore, MEG3 was found to be downregulated by another 
lncRNA, EWSAT1, which had previously been shown to enhance 
cell proliferation and metastasis in both osteosarcoma and Ewing 
sarcoma (Howarth et al., 2014; Sun et al., 2016).
In retinoblastoma, HOTAIR, THOR, and MEG3 appear to 
have a similar influence as seen in osteosarcoma, where they also 
acted as oncogenes (HOTAIR and THOR) or tumor suppressors 
(MEG3) (Gao et al., 2017; Shang, 2018; Yang G. et al., 2018). In 
the study examining HOTAIR in retinoblastoma, HOTAIR was 
shown to be engaged in a reciprocal regulatory loop with miR-
613 and promoted cell proliferation and activation of the EMT, 
potentially through upregulation of N-cadherin, vimentin, and 
α‐SMA (Yang G. et al., 2018). Several lncRNAs have also been 
found acting as oncogenic ceRNAs including XIST, DANCR, 
and HOXA11-AS (Hu et al., 2018; Wang J. X. et al., 2018; Han 
et al., 2019). Finally, PANDAR is upregulated in retinoblastoma 
and may regulate cell proliferation and apoptosis via the Bcl-2/
caspase-3 pathway (Sheng et al., 2018).
A number of studies have also suggested an important role 
for lncRNAs in neuroblastoma. For example, lncUSMYcN is 
an lncRNA that is frequently co-amplified alongside MYCN 
(Liu P. Y. et  al., 2016). Liu et al. found that in neuroblastoma, 
lncUSMycN could upregulate MYCN through transcriptional 
activation of NCYM (a.k.a. MYCNOS), which codes for a protein 
that stabilizes MYCN (Suenaga et al., 2014). NCYM RNA has also 
been suggested to bind to the RNA-binding protein NonO, which 
is also known to upregulate MYCN expression (Liu et al., 2014; 
Liu P. Y. et al., 2016). Neuroblastoma associated transcript-1 
(NBAT-1) is an epigenetic regulator that interacts with EZH2, 
and functions as a tumor suppressor due to its important role in 
neuronal differentiation (Pandey et al., 2014). Loss of NBAT-1 
expression was found to increase cell proliferation and invasion 
(Pandey et al., 2014). Finally, an isoform of lncRNA CASC15, 
CASC15-S, was also implicated as a key element in neuronal 
differentiation, and low expression was associated with a poor 
outcome in patients (Russell et al., 2015).
In Wilms tumor, a study by Zhu et al. identified LINC00473 
as an oncogenic lncRNA that is upregulated in unfavorable 
tumors (Zhu et al., 2018b). LINC00473 was shown to promote 
tumor growth and metastasis by acting as a ceRNA for the tumor 
suppressor miR-195 (Zhu et al., 2018b).
A study by Dong et al. identified 1757 upregulated and 
979 downregulated lncRNAs comparing hepatoblastoma and 
normal tissues, suggesting that lncRNAs play a key role in this 
disease as well (Dong et al., 2014). The lncRNAs Colorectal 
Neoplasia Differentially Expressed (CRNDE) and LINC01314 
have been investigated in more detail in hepatoblastoma 
(Dong et al., 2017; Lv et al., 2018). CRNDE is known to be 
frequently upregulated in hepatoblastoma, and knockdown 
of CRNDE activated the mTOR pathway and inhibited tumor 
growth and angiogenesis with a corresponding decrease in 
VEGFA and Ang-2 levels (Dong et al., 2017). LINC01314 was 
identified as a tumor suppressor, reducing proliferation and 
migration via downregulation of cell cycle proteins MCM7 
and cyclin D1 (Lv et al., 2018).
CONCLUDING REMARKS
It is now clear that both miRNAs and lncRNAs form integral 
parts of the biological networks known to be impaired in 
pediatric solid tumors. miRNAs such as let-7 and mir-34 are key 
regulators of many pediatric oncogenes including MYC, MYCN, 
RAS, and MET (Johnson et al., 2005; Wei et al., 2008; Buechner 
et al., 2011; Yan et al., 2012). Additionally, ncRNAs such as the 
miR-17~92 cluster, mir-9, and Malat1 also serve as downstream 
effectors of MYC and MYCN (Schulte et al., 2008; Ma et al., 2010; 
Tee et al., 2014). Many more ncRNAs participate in these and 
other pathways to form a highly complex regulatory network 
essential for maintaining an optimal cell state (See Tables 1 
and 2). ncRNA dysregulation offers an alternative mechanism 
to genetic mutations and DNA methylation whereby cell 
development and differentiation can be disturbed. Despite the 
relatively rare occurrence of mutations in pediatric solid tumors, 
copy number variations are common and often occur at regions 
of the genome that harbor ncRNAs with tumor-suppressive 
roles (Wei et al., 2008; Powers et al., 2016). Gene expression is 
often imprecise; however, miRNAs provide a layer of robustness, 
which helps ensure that biological networks respond appropriately 
to signals and remain functional despite an ever-increasing cellular 
disorder (Ebert and Sharp, 2012). lncRNAs, too, play a vital 
role in maintaining order by forming RNA–protein complexes 
and serving as ceRNA antagonists against miRNA-mediated 
repression, although much more work is needed in this field 
to fully comprehend their range of biological roles. Functional 
studies have revealed that dysregulation of ncRNAs is capable of 
driving progenitor cells towards oncogenesis. For example, this has 
been shown in retinoblastoma, where overexpression of the mir-
17~92 cluster could drive tumor formation in RB/p107-deficient 
mice (Conkrite et al., 2011).
While genome-wide association studies have revealed that 
miRNA processing is frequently disrupted in Wilms tumor, 
this has not been shown to the same extent in other pediatric 
solid tumors. However, genetic mutations of protein-coding 
genes are only one way in which disruptions of miRNA 
processing can be revealed. Most miRNA studies ignore the 
fact that a high proportion of expressed miRNAs are isoforms 
(isomiRs). isomiRs originating from the same miRNA gene can 
possess a great deal of functional variability, with differences in 
target acquisition or turnover rate that can have a significant 
impact on overall gene regulation. Studies focusing on isomiR 
expression will provide an additional layer of resolution to our 
understanding of miRNA dysregulation.
Recent developments in single-cell technology have revealed 
heterogeneity in gene expression profiles among individual 
cells in many cancers such as glioblastoma and neuroblastoma 
(Patel et al., 2014; Boeva et al., 2017). Such studies suggest 
that many tumors comprise different cellular subtypes with 
unique phenotypes such as growth rate, drug resistance, and 
metastatic potential, which demand a new way of approaching 
cancer treatments. miRNA expression in pediatric solid tumors 
may also be heterogenous; however, limitations in single-cell 
technologies have left this avenue relatively unexplored, and 
further developments are needed. 
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So far, ncRNA research has played a key role in advancing 
our understanding of the mechanisms behind pediatric 
solid tumor development. Evidence supports an active role 
for ncRNAs in cancer that extends beyond mere passengers. 
However, continued research is needed to fully comprehend 
the molecular events leading to the development of cancer 
and unlock new possibilities for drug targets and biomarkers, 
which will ultimately lead to a better outcome for patients 
afflicted by these diseases. 
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